Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

85,173 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Deep Learning Predicts Overall Survival of Patients With Unresectable Hepatocellular Carcinoma Treated by Transarterial Chemoembolization Plus Sorafenib.
Zhang L, Xia W, Yan ZP, Sun JH, Zhong BY, Hou ZH, Yang MJ, Zhou GH, Wang WS, Zhao XY, Jian JM, Huang P, Zhang R, Zhang S, Zhang JY, Li Z, Zhu XL, Gao X, Ni CF. Zhang L, et al. Among authors: zhang r, zhang s, zhang jy. Front Oncol. 2020 Sep 30;10:593292. doi: 10.3389/fonc.2020.593292. eCollection 2020. Front Oncol. 2020. PMID: 33102242 Free PMC article.
Prognosis Nomogram for Hepatocellular Carcinoma Patients with Portal Vein Invasion Undergoing Transarterial Chemoembolization Plus Sorafenib Treatment: A Retrospective Multicentre Study.
Zhang L, Sun JH, Hou ZH, Zhong BY, Yang MJ, Zhou GH, Wang WS, Huang P, Zhang S, Li Z, Zhu XL, Yan ZP, Ni CF. Zhang L, et al. Among authors: zhang s. Cardiovasc Intervent Radiol. 2021 Jan;44(1):63-72. doi: 10.1007/s00270-020-02579-2. Epub 2020 Sep 23. Cardiovasc Intervent Radiol. 2021. PMID: 32965582
Prognostic Performance of Albumin-Bilirubin Grade With Artificial Intelligence for Hepatocellular Carcinoma Treated With Transarterial Chemoembolization Combined With Sorafenib.
Zhong BY, Yan ZP, Sun JH, Zhang L, Hou ZH, Yang MJ, Zhou GH, Wang WS, Li Z, Huang P, Zhang S, Zhu XL, Ni CF. Zhong BY, et al. Among authors: zhang l, zhang s. Front Oncol. 2020 Dec 18;10:525461. doi: 10.3389/fonc.2020.525461. eCollection 2020. Front Oncol. 2020. PMID: 33392064 Free PMC article.
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Predictors of Outcomes in Patients With Unresectable Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Plus Sorafenib.
Zhang L, Yan ZP, Hou ZH, Huang P, Yang MJ, Zhang S, Zhang S, Zhang SH, Zhu XL, Ni CF, Li Q. Zhang L, et al. Among authors: zhang sh, zhang s. Front Mol Biosci. 2021 May 28;8:624366. doi: 10.3389/fmolb.2021.624366. eCollection 2021. Front Mol Biosci. 2021. PMID: 34124139 Free PMC article.
Corrigendum: Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Predictors of Outcomes in Patients With Unresectable Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Plus Sorafenib.
Zhang L, Yan ZP, Hou ZH, Huang P, Yang MJ, Zhang S, Zhang S, Zhang SH, Zhu XL, Ni CF, Li Q. Zhang L, et al. Among authors: zhang sh, zhang s. Front Mol Biosci. 2021 Aug 30;8:727969. doi: 10.3389/fmolb.2021.727969. eCollection 2021. Front Mol Biosci. 2021. PMID: 34527705 Free PMC article.
85,173 results
You have reached the last available page of results. Please see the User Guide for more information.